The JAK inhibitor 'Jyseleca' has been successfully introduced to general hospitals.

Sources said Jyseleca, the fifth JAK inhibitor in South Korea, has passed the drug committees (DC) of 'Big 5' tertiary hospitals, including Samsung Medical Center, Seoul University Hospital, Seoul St. Mary's Hospital, Seoul Asan Medical Center, and Sinchon Severance Hospital. The drug also passed DC of medical centers, including Kangbuk Samsung Hospital, Korea University Anam Hospital, Cha University Bundang Medical Center, Sejong Chungnam National University Hospital, Ulsan University Hospital, Konkuk University Hospital Chungju Hospital, and Hanyang University Medical Center, as well as national university hospitals